Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Enrollment complete in pivotal phase III trial of FavId for follicular B-cell NHL
February 27th, 2006
Favrille, Inc., (FVRL), a biopharmaceutical company developing patient-specific immunotherapies for the treatment of cancer, announced that it has completed enrollment in the company's pivotal phase III clinical trial of FavId. Initiated in July 2004, the registration trial is designed to evaluate FavId following Rituxan therapy for the treatment of follicular B-cell non-Hodgkin lymphoma (NHL). "To complete enrollment in just 18 months is a significant accomplishment and a credit to everyone involved in the trial," said John F. Bender, PharmD, senior vice-president of clinical research. "The rapid enrollment supports our belief that an all-biologic...
Source: Pharma Business Week (2006-02-27)
|
